Search
Novabridge Biosciences ADR
NBPAdd to Watchlist
1.215USD
-0.155-11.31%
Close 10-26 16:00（ET）
140.05MMarket Cap
LossP/E TTM
NBP Analyst Recommendation Trends
In the current month, NBP has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NBP average Analyst price target in the last month is 8.667.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
2
2
2
2
2
2
2
2
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
5
5
5
5
5
5
Financial Forecasting
Based on analysts' estimates, NBP EPS is projected to reach -0.130 in FY2026Q1, following reported EPS of -0.266 in FY2025Q4. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
--
-0.05
-0.13
-0.14
-0.08
-0.08
Actual
-0.07
-0.27
--
--
--
--
Surprise
--
-407.49%
--
--
--
--
FAQs
How have Novabridge Biosciences ADRNBP's recent earnings per share performed?
The market expectation was USD -0.27, while Novabridge Biosciences ADRNBP's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for Novabridge Biosciences ADR?
Based on the ratings of Novabridge Biosciences ADR's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.